The global non-invasive aesthetic treatment market size accounted for USD 22.67 billion in 2025 and is forecasted to hit around USD 41.55 billion by 2034, representing a CAGR of 7.00% from 2025 to 2034. The North America market size was estimated at USD 9.00 billion in 2024 and is expanding at a CAGR of 7.10% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Non-Invasive Aesthetic Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Non-Invasive Aesthetic Treatment Market, by Procedure Type, 2024-2033
8.1.1. Injectable
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Skin Rejuvenation
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2021-2033)
9.1. Non-Invasive Aesthetic Treatment Market, by End Use, 2024-2033
9.1.1. Hospitals & Surgery Centers
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Medical Spa
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Clinics
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2021-2033)
10.1. North America
10.1.1. Market Revenue and Forecast, by Procedure (2021-2033)
10.1.2. Market Revenue and Forecast, by End Use (2021-2033)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Procedure (2021-2033)
10.1.3.2. Market Revenue and Forecast, by End Use (2021-2033)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Procedure (2021-2033)
10.1.4.2. Market Revenue and Forecast, by End Use (2021-2033)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Procedure (2021-2033)
10.2.2. Market Revenue and Forecast, by End Use (2021-2033)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Procedure (2021-2033)
10.2.3.2. Market Revenue and Forecast, by End Use (2021-2033)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Procedure (2021-2033)
10.2.4.2. Market Revenue and Forecast, by End Use (2021-2033)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Procedure (2021-2033)
10.2.5.2. Market Revenue and Forecast, by End Use (2021-2033)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Procedure (2021-2033)
10.2.6.2. Market Revenue and Forecast, by End Use (2021-2033)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Procedure (2021-2033)
10.3.2. Market Revenue and Forecast, by End Use (2021-2033)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Procedure (2021-2033)
10.3.3.2. Market Revenue and Forecast, by End Use (2021-2033)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Procedure (2021-2033)
10.3.4.2. Market Revenue and Forecast, by End Use (2021-2033)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Procedure (2021-2033)
10.3.5.2. Market Revenue and Forecast, by End Use (2021-2033)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Procedure (2021-2033)
10.3.6.2. Market Revenue and Forecast, by End Use (2021-2033)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Procedure (2021-2033)
10.4.2. Market Revenue and Forecast, by End Use (2021-2033)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Procedure (2021-2033)
10.4.3.2. Market Revenue and Forecast, by End Use (2021-2033)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Procedure (2021-2033)
10.4.4.2. Market Revenue and Forecast, by End Use (2021-2033)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Procedure (2021-2033)
10.4.5.2. Market Revenue and Forecast, by End Use (2021-2033)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Procedure (2021-2033)
10.4.6.2. Market Revenue and Forecast, by End Use (2021-2033)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Procedure (2021-2033)
10.5.2. Market Revenue and Forecast, by End Use (2021-2033)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Procedure (2021-2033)
10.5.3.2. Market Revenue and Forecast, by End Use (2021-2033)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Procedure (2021-2033)
10.5.4.2. Market Revenue and Forecast, by End Use (2021-2033)
11.1. Galderma S.A.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Allergen
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. El. En. SpA
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Alma Lasers
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Johnson & Johnson
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Cynosure
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Solta Medical
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Syneron Candela
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Lumenis
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Merz Pharma
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description